GSA Capital Partners LLP Purchases Shares of 28,584 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

GSA Capital Partners LLP purchased a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 28,584 shares of the company’s stock, valued at approximately $824,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Assenagon Asset Management S.A. raised its holdings in Apellis Pharmaceuticals by 191.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock valued at $61,845,000 after acquiring an additional 1,409,707 shares in the last quarter. Iron Triangle Partners LP bought a new stake in shares of Apellis Pharmaceuticals during the first quarter valued at approximately $32,329,000. Fiera Capital Corp lifted its position in Apellis Pharmaceuticals by 47.7% in the second quarter. Fiera Capital Corp now owns 1,401,190 shares of the company’s stock worth $53,750,000 after purchasing an additional 452,753 shares during the period. AQR Capital Management LLC boosted its stake in Apellis Pharmaceuticals by 337.3% during the second quarter. AQR Capital Management LLC now owns 246,880 shares of the company’s stock worth $9,177,000 after buying an additional 190,420 shares in the last quarter. Finally, Redmile Group LLC bought a new stake in Apellis Pharmaceuticals in the 1st quarter valued at $9,111,000. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Stock Performance

APLS stock opened at $26.27 on Friday. The company has a 50 day moving average price of $29.93 and a 200 day moving average price of $36.25. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $24.34 and a fifty-two week high of $73.80. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The stock has a market capitalization of $3.27 billion, a PE ratio of -12.94 and a beta of 0.87.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). The firm had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company’s revenue was up 78.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.17) EPS. Analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 37,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the sale, the director now directly owns 100,000 shares of the company’s stock, valued at $3,623,000. The trade was a 27.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 6.80% of the company’s stock.

Wall Street Analyst Weigh In

APLS has been the subject of a number of analyst reports. Bank of America reduced their price objective on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. HC Wainwright decreased their price objective on Apellis Pharmaceuticals from $83.00 to $57.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. UBS Group dropped their target price on Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating for the company in a report on Friday, August 9th. Robert W. Baird decreased their price target on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. Finally, William Blair began coverage on Apellis Pharmaceuticals in a research report on Wednesday, October 16th. They issued an “outperform” rating on the stock. Six analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $51.06.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).